/
INKT
$11.91+$0.27 (+2.32%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$58.0M
5M shares
52-week range
$6.80 – $76.00
7% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
16.05%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-108.09
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $689.6K | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $55.1K | $78.0K | $121.7K | $204.6K | $215.4K | $181.7K |
| Gross profit | $689.6K | −$55.1K | −$78.0K | −$121.7K | −$204.6K | −$215.4K | −$181.7K |
| Gross margin | 100.0% | — | — | — | — | — | — |
| R&D | $19.7M | $9.5M | $14.0M | $23.1M | $15.5M | $6.3M | $5.76B |
| Operating income | −$22.3M | −$10.8M | −$18.6M | −$30.9M | −$22.9M | −$10.7M | −$12.5M |
| EBITDA | −$22.2M | −$13.7M | −$27.7M | −$27.9M | −$22.3M | −$10.6M | −$12.3M |
| Net income | −$23.8M | −$16.2M | −$30.2M | −$28.0M | −$22.5M | −$10.8M | −$12.5M |
| Net margin | -3451.5% | — | — | — | — | — | — |
| EPS (diluted) | -10.80 | -4.91 | -9.03 | -8.31 | -6.54 | -2.80 | -2.93 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $125000 | $-2.75 | $-3.02–$-2.46 | 1 |
| 2027 | $4M | $-2.85 | $-3.31–$-2.39 | 2 |
| 2028 | $2M | $-3.49 | $-4.11–$-2.87 | 2 |
| 2029 | $28M | $-2.84 | $-2.84–$-2.84 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.16
Price
$11.91
Implied downside
-90%
Peer comparison
MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
www.minktherapeutics.com- Employees
- 15
- IPO / List date
- Oct 15, 2021
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds INKT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 10,400 | $116.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-01-28 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded INKT yet.
